News archive 2009

17 December 2009
AGENDIA - FDA Broadens Clearance for MammaPrint

9 December 2009
Gilde Healthcare Partners raises growth capital fund dedicated to healthcare services

3 December 2009
SANTARIS PHARMA - New data show breakthrough microRNA-targeted therapy holds promise as new treatment for hepatitis C

3 December 2009
AGENDIA - Breast Cancer Recurrence Test MammaPrint included in Medicare reimbursement guidelines

2 December 2009
ABLYNX will receive further milestone payments of EUR 3 million as part of its alliance with Boehringer Ingelheim

2 December 2009
AMT Announces Management Changes in light of refocused strategy

18 November 2009
INNATE PHARMA initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID® combined with Anti-KIR antibody IPH 2101 in patients with multiple myeloma

17 November 2009
BG MEDICINE and Abbott announce a development and commercialization agreement for galectin-3 biomarker

3 November 2009
Symphogen Opens US Operations in Princeton, New Jersey

21 October 2009
FlowCardia, Inc. expands treatment options for patients with chronic total occlusion

6 October 2009
FlowCardia, Inc. Launches FlowMate™ Injector to Optimize Performance of CROSSER® CTO Recanalization Catheter

5 October 2009
GILDE HEALTHCARE II invests in mtm laboratories AG

1 October 2009
Ablynx receives milestone payments from Boehringer Ingelheim and Wyeth

24 September 2009
AMT Appoints New Chief Executive Officer

22 September 2009
Agendia raises EUR 16.6 million (USD 23 million) in series E financing

16 September 2009
New collaborations and breakthrough advancements in RNA-based drug development programs lead Santaris Pharma A/S to establish US operations

15 September 2009
Pieris AG enters into Anticalin Collaboration with Allergan, Inc.

24 August 2009
Santaris Pharma A/S forms strategic alliance with Shire plc to develop RNA-based medicines for the treatment of rare genetic disorders

24 August 2009
Gilde Healthcare Partners leads EUR 8 million series B financing in Profibrix B.V.

18 August 2009
ABLYNX Announces positive Phase I results for subcutaneous administration of its anti-thrombotic NANOBODY® (ALX-0681)

17 August 2009
Symphogen Appoints Adriann Sax Chief Business Officer

7 July 2009
BG MEDICINE and Humana Enroll More Than 6,800 Participants in BioImage Study Focused on Heart Attack Prediction

29 June 2009
Innate Pharma reports positive phase IIa in type C viral hepatitis

24 June 2009
Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis

23 June 2009
Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations

23 June 2009
Chroma Therapeutics completes £15 million Series D financing

23 June 2009
Chroma Therapeutics signs $1 billion deal with GlaxoSmithKline

18 June 2009
AMT - Glybera(TM) Shows Long-Term Health Benefits

8 June 2009
Acacia Pharma initiates Phase II study with APD405 in post-operative nausea & vomiting (PONV)

4 June 2009
SANTARIS - LNA-based HIF-1 alpha inhibitor shows early signs of clinical benefit

28 May 2009
AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria

26 May 2009
Agendia Opens CLIA-Registered U.S. Genomics Laboratory Agendia Increases U.S. Footprint with Domestic Executive Team and Operations

2 April 2009
IDEA reports results from a prospective 3 years phase III study of Diractin® (ketoprofen in Transfersome® gel)

31 March 2009
Acacia Pharma initiates Phase IIa study with APD209 in cancer cachexia patients

31 March 2009
BG Medicine Inc. launches Galectin-3 Website and Commences Galectin-3 Assay Service for Clinical Research

6 March 2009
SYMPHOGEN and Origen Collaborate to Produce Transgenic Chicken for generation of Fully Human Antibody Therapeutics

5 March 2009
AGENDIA Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board

3 March 2009
BG MEDICINE Appoints Doug White as Executive Vice President & General Manager, Diagnostics

18 February 2009
AGENDIA Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer

5 February 2009
ACACIA PHARMA Appoints Ian Kent as Chairman

5 February 2009
IDEA AG - US Patent Office grants a new patent, which also covers the targeted analgesic product Diractin®

5 February 2009
ABLYNX Announces Second Extension of its NANOBODY® Drug Discovery and Development Alliance

4 February 2009
SYMPHOGEN Secures EUR 33 million Financing to Support Clinical Development of Antibody Products

3 February 2009
ABLYNX Receives EUR 3 million in Milestone Payments

3 February 2009
PIERIS reports development progress for Anticalin® PRS-050, a next generation VEGF antagonist

29 January 2009
SYMPHOGEN Adds Receptor’s Pan-HER Ligand Trap Technology to Diversify Recombinant Polyclonal Antibody Portfolio - both Technology Platforms Explicitly Target Disease Complexity

28 January 2009
AMT: Glybera® Lowers Pancreatitis Incidence Significantly

22 January 2009
AMT CEO Ronald Lorijn Steps Down - Sander van Deventer Interim CEO

20 January 2009
ABLYNX Expands its Musculoskeletal Portfolio by Taking P&G Pharmaceutical’s Programme In-House

14 January 2009
ABLYNX announces Technical Advances in its NANOBODY® Platform: Enhanced Benefits from Pulmonary Delivery and Half-Life Extension

12 January 2009
Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines

8 January 2009
ABLYNX Strengthens Management Team with the Appointment of Dr Debbie Law as Chief Scientific Officer

6 January 2009
Acacia Pharma completes clinical trial with APD 405 for nausea & vomiting

Bottles with golden caps